Rezvilutamide：首次获批准。
Rezvilutamide: First Approval.
发表日期：2023 Feb
作者：
Susan J Keam
来源：
DRUGS
摘要：
Rezvilutamide（®）是江苏恒瑞医药股份有限公司开发的口服二代雄激素受体拮抗剂，用于治疗前列腺癌。2022年6月，中国批准使用rezvilutamide治疗具有高肿瘤负担的转移性激素敏感性前列腺癌（mHSPC）患者。本文总结了rezvilutamide开发的里程碑，引领了针对前列腺癌患者的首次批准。© 2023年。作者在Springer Nature Switzerland AG的独家许可下。
Rezvilutamide (®) is an oral, second-generation androgen receptor antagonist being developed by Jiangsu Hengrui Medicine Co., Ltd for the treatment of prostate cancer. In June 2022, rezvilutamide was approved in China for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with high tumour burden. This article summarizes the milestones in the development of rezvilutamide leading to this first approval for patients with prostate cancer.© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.